Ekaterina Karpuzova, country commercial lead pharmaceuticals at Bayer Bulgaria, explains how the national healthcare system has evolved over the last few years as well as demonstrates the commitment of Bayer Bulgaria to supporting the impact and quality of its solutions through value-based evidence.
After starting in Bayer Bulgaria, you went to Germany and Slovakia in 2011 and came back last year in 2016. How has the Bulgarian pharmaceutical sector changed during those five years?
"Oncology and cardiology are the two main pillars of Bayer and this needs to be also reflected here."
